Annals of Surgical Oncology

, Volume 14, Issue 12, pp 3359–3368 | Cite as

Quantification and Phenotypic Characterization of Circulating Tumor Cells for Monitoring Response to a Preventive HER2/neu Vaccine-Based Immunotherapy for Breast Cancer: A Pilot Study

  • Alexander Stojadinovic
  • Elizabeth A. Mittendorf
  • Jarrod P. Holmes
  • Asna Amin
  • Matthew T. Hueman
  • Sathibalan Ponniah
  • George E. Peoples
Breast Oncology Original Papers

Abstract

Background

Ongoing cancer vaccine trials are limited by the inability of immunologic assays to monitor clinically relevant surrogates of response. Recent advances in the ability to quantify and phenotype circulating tumor cells (CTCs) in breast cancer patients may lead to a role for CTCs in monitoring response to vaccine-based immunotherapy.

Methods

The CellSearch System (Veridex-LLC, Warren, NJ) was used to enumerate total and HER2/neu+ CTCs in 20 mL of blood from all 16 node-positive (NP) breast cancer patients active in our NP HER2/neu E75 peptide vaccine trial at the initiation of this pilot study. These patients were vaccinated with E75 (1000 μg)/GM-CSF (250 μg) monthly × 6 after completion of multimodality therapy. Mean (±SEM) number of CTCs and HER2/neu+ CTCs were compared in unmatched (n = 16) and matched (n = 9) prevaccination and postvaccination cases.

Results

CTCs were detected in 14 of 16 (88%) patients (mean: 3.4 ± 0.2 CTC/20 mL). After vaccination, a reduction in CTC/20 mL (prevaccination 3.9 ± 1.5 vs postvaccination 0.7 ± 0.4, P = .077) and HER2/neu+ CTC/20 mL (prevaccination 2.8 ± 1.0 vs postvaccination 0.5 ± 0.2, P = .048) was demonstrated. A significant delayed-type hypersensitivity (DTH) response suggesting that vaccination was effective in eliciting a peptide-specific immune response was confirmed (22.3 ± 4.1 vs 3.0 ± 2.2 [controls] mm, P < .01). All nine patients followed throughout the vaccination series also showed significant reduction in CTCs (4.8 ± 1.5 vs 0.3 ± 0.2, P < .01) and HER2/neu+ CTCs (3.0 ± 0.9 vs 0.4 ± 0.2, P = .013).

Conclusions

CTCs are readily demonstrated in posttreatment, clinically disease-free NP breast cancer patients. E75+GM-CSF vaccination appears to reduce the number of CTCs. These data suggest a potential role for this clinically validated CTC assay in assessing response to preventive vaccine-based immunotherapy, and further validation studies are underway.

Keywords

Breast cancer Peptide Vaccine Circulating tumor cells 

References

  1. 1.
    Slamon DJ, Godolphin W, Jones LA, et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989; 244:707–12PubMedCrossRefGoogle Scholar
  2. 2.
    Peoples GE, Goedegebuure PS, Smith R, Linehan DC, Yoshino I, Eberlein TJ. Breast and ovarian cancer-specific cytotoxic T lymphocytes recognize the same HER2/neu-derived peptide. Proc Natl Acad Sci USA 1995; 92:432–6PubMedCrossRefGoogle Scholar
  3. 3.
    Disis ML, Schiffman K, Guthrie K, et al. Effect of dose on immune response in patients vaccinated with an HER-2/neu intracellular domain protein-based vaccine. J Clin Oncol 2004; 22:1916–25PubMedCrossRefGoogle Scholar
  4. 4.
    Murray JL, Przepiorka D, Ioannides CG. Clinical trials of HER-2/neu-specific vaccines. Semin Oncol 2000; 27 Suppl 11:71–5PubMedGoogle Scholar
  5. 5.
    Correa I, Plunkett T. Update on HER-2 as a target for cancer therapy: HER2/neu peptides as tumour vaccines for T cell recognition. Breast Cancer Res 2001; 3:399–403PubMedCrossRefGoogle Scholar
  6. 6.
    Mittendorf EA, Gurney JM, Storrer CE, Shriver CD, Ponniah S, Peoples GE. Vaccination with a HER2/neu peptide induces intra- and inter-antigenic epitope spreading in patients with early stage breast cancer. Surgery 2006; 139:407–18PubMedCrossRefGoogle Scholar
  7. 7.
    Peoples GE, Gurney JM, Hueman MT, et al. Clinical trial results of a HER2/neu (E75) vaccine to prevent recurrence in high-risk breast cancer patients. J Clin Oncol 2005; 23:7536–45PubMedCrossRefGoogle Scholar
  8. 8.
    Fisk B, Blevins TL, Wharton JT, Ioannides CG. Identification of an immunodominant peptide of HER-2/neu protooncogene recognized by ovarian tumor-specific cytotoxic T lymphocyte lines. J Exp Med 1995; 181:2109–17PubMedCrossRefGoogle Scholar
  9. 9.
    Zaks TZ, Rosenberg SA. Immunization with a peptide epitope (p369–377) from HER-2/neu leads to peptide-specific cytotoxic T lymphocytes that fail to recognize HER-2/neu+ tumors. Cancer Res 1998; 58:4902–8PubMedGoogle Scholar
  10. 10.
    Knutson KL, Schiffman K, Cheever MA, Disis ML. Immunization of cancer patients with a HER-2/neu, HLA-A2 peptide, p369–377, results in short-lived peptide-specific immunity. Clin Cancer Res 2002; 8:1014–8PubMedGoogle Scholar
  11. 11.
    Murray JL, Gillogly ME, Przepiorka ME, et al. Toxicity, immunogenicity, and induction of E75-specific tumor-lytic CTLs by HER-2 peptide E75 (369–377) combined with granulocyte macrophage colony-stimulating factor in HLA-A2+ patients with metastatic breast and ovarian cancer. Clin Cancer Res 2002; 8:3407–18PubMedGoogle Scholar
  12. 12.
    Peoples GE, Khoo S, Dehqanzada ZA, et al. Combined clinical trial results of a HER2/neu (E75) vaccine for prevention of recurrence in high-risk breast cancer patients. Breast Cancer Res Treat 2006; 100 (Suppl 1):S6(Abstract 4)Google Scholar
  13. 13.
    Woll MM, Fisher CM, Ryan GB, et al. Direct measurement of peptide-specific CD8+ T cells using HLA-A2:Ig dimer for monitoring the in vivo immune response to a HER2/neu vaccine in breast and prostate cancer patients. J Clin Immunol 2004; 24:449–61PubMedCrossRefGoogle Scholar
  14. 14.
    Keilholz U, Martus P, Scheibenbogen C. Immune monitoring of T-cell responses in cancer vaccine development. Clin Cancer Res 2006; 12:2346s–52sPubMedCrossRefGoogle Scholar
  15. 15.
    Hoos A, Parmiani G, Hege K, et al. A clinical development paradigm for cancer vaccines and related biologics. J Immunother 2007; 30:1–15PubMedCrossRefGoogle Scholar
  16. 16.
    Riethdorf S, Fritsche H, Müller V, et al. Detection of circulating tumor cells in peripheral blood of patients with metastatic breast cancer: a validation study of the CellSearch System. Clin Cancer Res 2007; 13:920–8PubMedCrossRefGoogle Scholar
  17. 17.
    Cristofanilli M, Budd GT, Ellis MJ, et al. Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med 2004; 351:781–91PubMedCrossRefGoogle Scholar
  18. 18.
    Cristofanilli M, Hayes DF, Budd GT, et al. Circulating tumor cells: a novel prognostic factor for newly diagnosed metastatic breast cancer. J Clin Oncol 2005; 23:1420–30PubMedCrossRefGoogle Scholar
  19. 19.
    Hayes DF, Cristofanilli M, Budd GT, et al. Circulating tumor cells at each follow-up time point during therapy of metastatic breast cancer patients predict progression-free and overall survival. Clin Cancer Res 2006; 12:4218–24PubMedCrossRefGoogle Scholar
  20. 20.
    Kahn HJ, Presta A, Yang LY, et al. Enumeration of circulating tumor cells in the blood of breast cancer patients after filtration enrichment: correlation with disease stage. Breast Cancer Res Treat 2004; 86:237–47PubMedCrossRefGoogle Scholar
  21. 21.
    Meng S, Tripathy D, Frenkel EP, et al. Circulating tumor cells in patients with breast cancer dormancy. Clin Cancer Res 2004; 10:8152–62PubMedCrossRefGoogle Scholar

Copyright information

© Society of Surgical Oncology 2007

Authors and Affiliations

  • Alexander Stojadinovic
    • 1
    • 2
  • Elizabeth A. Mittendorf
    • 3
  • Jarrod P. Holmes
    • 2
    • 4
  • Asna Amin
    • 2
    • 5
  • Matthew T. Hueman
    • 2
    • 5
  • Sathibalan Ponniah
    • 2
  • George E. Peoples
    • 2
    • 6
  1. 1.Department of SurgeryWalter Reed Army Medical CenterWashingtonUSA
  2. 2.Cancer Vaccine Development ProgramUnited States Military Cancer Institute, Uniformed Services University of the Health SciencesBethesdaUSA
  3. 3.Surgical Oncology, Department of SurgeryU.T.M.D. Anderson Cancer CenterHoustonUSA
  4. 4.Hematology/Oncology, Department of MedicineNational Naval Medical CenterBethesdaUSA
  5. 5.General Surgery, Department of SurgeryWalter Reed Army Medical CenterWashingtonUSA
  6. 6.Surgical Oncology, Department of SurgeryBrooke Army Medical CenterHoustonUSA

Personalised recommendations